ECSP21087884A - Inhibidores de kcnt1 y métodos de uso - Google Patents

Inhibidores de kcnt1 y métodos de uso

Info

Publication number
ECSP21087884A
ECSP21087884A ECSENADI202187884A ECDI202187884A ECSP21087884A EC SP21087884 A ECSP21087884 A EC SP21087884A EC SENADI202187884 A ECSENADI202187884 A EC SENADI202187884A EC DI202187884 A ECDI202187884 A EC DI202187884A EC SP21087884 A ECSP21087884 A EC SP21087884A
Authority
EC
Ecuador
Prior art keywords
kcnt1
methods
inhibitors
disease
disorder
Prior art date
Application number
ECSENADI202187884A
Other languages
English (en)
Inventor
Andrew Griffin
Michael Kristopher Kahlig
Kiran Reddy
Botella Gabriel Martinez
Paul Charifson
Brian Marron
Original Assignee
Praxis Prec Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Prec Medicines Inc filed Critical Praxis Prec Medicines Inc
Publication of ECSP21087884A publication Critical patent/ECSP21087884A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención está dirigida, en parte, a compuestos y composiciones útiles para prevenir y/o tratar una enfermedad o trastorno neurológico, una enfermedad o afección relacionada con excitabilidad neuronal excesiva y/o una mutación de ganancia de función en un gen (por ejemplo, KCNT1). También se proporcionan en la presente descripción métodos para tratar una enfermedad o trastorno neurológico, una enfermedad o afección relacionada con excitabilidad neuronal excesiva y/o una mutación de ganancia de función en un gen tal como KCNT1.
ECSENADI202187884A 2019-05-03 2021-12-03 Inhibidores de kcnt1 y métodos de uso ECSP21087884A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962842849P 2019-05-03 2019-05-03
US202062982864P 2020-02-28 2020-02-28

Publications (1)

Publication Number Publication Date
ECSP21087884A true ECSP21087884A (es) 2022-01-31

Family

ID=73051241

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202187884A ECSP21087884A (es) 2019-05-03 2021-12-03 Inhibidores de kcnt1 y métodos de uso

Country Status (17)

Country Link
US (1) US20220259193A1 (es)
EP (1) EP3962481A4 (es)
JP (2) JP7667573B2 (es)
KR (1) KR20220016086A (es)
CN (2) CN114269340A (es)
AU (1) AU2020267356B2 (es)
BR (1) BR112021022067A2 (es)
CA (1) CA3139063A1 (es)
CL (2) CL2021002877A1 (es)
CO (1) CO2021016471A2 (es)
EC (1) ECSP21087884A (es)
IL (1) IL287768A (es)
MX (1) MX2021013421A (es)
PE (1) PE20220016A1 (es)
SA (1) SA521430751B1 (es)
SG (1) SG11202112158YA (es)
WO (1) WO2020227101A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12590083B2 (en) 2019-01-25 2026-03-31 University Of Virginia Patent Foundation Inhibitors of spinster homolog 2 (SPNS2) for use in therapy
IL317949A (en) * 2019-05-03 2025-02-01 Praxis Prec Medicines Inc KCNT1 inhibitors and methods of use
KR20230005813A (ko) * 2020-02-28 2023-01-10 프락시스 프리시젼 메디신즈, 인크. Kcnt1 억제제 및 사용 방법
EP4210824A1 (en) * 2020-09-09 2023-07-19 University of Virginia Patent Foundation Inhibitors of spinster homolog 2 (spns2) for use in therapy
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
TW202227424A (zh) * 2020-11-27 2022-07-16 大陸商瑞石生物醫藥有限公司 芳基或雜芳基取代５員芳雜環化合物及其用途
EP4267133A4 (en) * 2020-12-22 2025-01-22 Praxis Precision Medicines, Inc. KCNT1 INHIBITORS AND METHODS OF USE
US20240368142A1 (en) * 2021-04-29 2024-11-07 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2022231872A1 (en) * 2021-04-29 2022-11-03 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2023211850A1 (en) * 2022-04-25 2023-11-02 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use
US20250360117A1 (en) * 2022-06-08 2025-11-27 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use
CN116813505B (zh) * 2023-06-29 2025-09-02 爱斯特（成都）生物制药股份有限公司 一种制备o-甲基-n-苄氧羰基-l-高丝氨酸的方法
AU2024390752A1 (en) * 2023-11-29 2026-05-14 Actio Biosciences, Inc. Heterocyclic compounds useful as kcnt1 inhibitors
US20260109692A1 (en) 2024-10-18 2026-04-23 UCB Biopharma SRL Kcnt1 inhibitors and methods of use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
JP2005060255A (ja) * 2003-08-20 2005-03-10 Nippon Nohyaku Co Ltd カルボキサミド類及びこれを有効成分とする有害生物防除剤
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
CA2658764A1 (en) * 2006-07-20 2008-01-24 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
KR20150131224A (ko) * 2013-03-14 2015-11-24 노파르티스 아게 돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
WO2016053855A1 (en) 2014-09-29 2016-04-07 The Scripps Research Institute Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders
WO2016153023A1 (ja) * 2015-03-25 2016-09-29 国立研究開発法人国立長寿医療研究センター 新規オキサジアゾール誘導体及びこれを含有する医薬
WO2017170826A1 (ja) * 2016-03-30 2017-10-05 味の素株式会社 グルカゴン様ペプチド－１受容体作用増強活性を有する化合物
US11731966B2 (en) * 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
KR20230005813A (ko) * 2020-02-28 2023-01-10 프락시스 프리시젼 메디신즈, 인크. Kcnt1 억제제 및 사용 방법
BR112022019041A2 (pt) * 2020-03-23 2022-12-27 Praxis Prec Medicines Inc Inibidores de kcnt1 e métodos de uso
WO2022010880A1 (en) * 2020-07-06 2022-01-13 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
US11773088B2 (en) * 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
EP4267133A4 (en) * 2020-12-22 2025-01-22 Praxis Precision Medicines, Inc. KCNT1 INHIBITORS AND METHODS OF USE
US20240368142A1 (en) * 2021-04-29 2024-11-07 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use

Also Published As

Publication number Publication date
EP3962481A4 (en) 2023-03-22
IL287768A (en) 2022-01-01
AU2020267356A1 (en) 2022-01-06
CN114269340A (zh) 2022-04-01
AU2020267356B2 (en) 2025-04-24
SG11202112158YA (en) 2021-12-30
US20220259193A1 (en) 2022-08-18
JP2025102975A (ja) 2025-07-08
SA521430751B1 (ar) 2024-02-01
KR20220016086A (ko) 2022-02-08
CN120817941A (zh) 2025-10-21
MX2021013421A (es) 2022-02-11
CO2021016471A2 (es) 2022-04-08
EP3962481A1 (en) 2022-03-09
JP2022531388A (ja) 2022-07-06
CL2021002877A1 (es) 2022-08-12
WO2020227101A1 (en) 2020-11-12
PE20220016A1 (es) 2022-01-11
CA3139063A1 (en) 2020-11-12
BR112021022067A2 (pt) 2022-05-17
JP7667573B2 (ja) 2025-04-23
CL2024002067A1 (es) 2024-12-13

Similar Documents

Publication Publication Date Title
ECSP21087657A (es) Inhibidores de kcnt1 y métodos de uso
CO2021016471A2 (es) Inhibidores de kcnt1 y métodos de uso
CO2021000151A2 (es) Inhibidores de pd-1/pd-l1
UY38613A (es) Inhibidores de la proteína tirosina fosfatasa y mètodos de uso de los mismos
MX2022004101A (es) Composiciones de oligonucleotidos y metodos de uso de las mismas.
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
DOP2020000154A (es) Inhibidores pd-1/pd-l1
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
MA43131B1 (fr) Compositions et procédés d'inhibition de l'activité de l'arginase
CO2021000447A2 (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso
TN2018000213A1 (en) Compounds useful as kinase inhibitors
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
MX2026000122A (es) Inhibidores de kcnt1 y metodos de uso
ATE448207T1 (de) Mitotische kinesin-hemmer
ATE356804T1 (de) Inhibitoren von mitotischem kinesin
BR112022017191A2 (pt) Inibidores de kcnt1 e métodos de uso
CO2020005417A2 (es) Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd
ECSP23057264A (es) Inhibidores de cdk2 y métodos de uso de los mismos
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
EA202092748A1 (ru) Модуляторы экспрессии apol1
MX2022002446A (es) Compuestos de pirrolopirimidina inhibidores de perk.
BR112022005895A2 (pt) Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2
MX2022007441A (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.
MX2023000360A (es) Inhibidores de kcnt1 y metodos de uso.
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa